Cortene's CT38 drug trial produces "encouraging results" in chronic fatigue syndrome as it finds that lower concentrations of the drug provide better effects - thus validating their hypothesis.
Cort talks about hot topics in fibromyalgia research, future treatment possibilities, diagnosis, the difference between chronic fatigue syndrome and FM and more to the Sheffield ME and Fibromyalgia Association in the UK.
A retrospective study suggests that low dose Abilify is safe and may be helpful in reducing fatigue and post-exertional malaise and improving cognition and sleep in chronic fatigue syndrome. A placebo-controlled study is needed to determine how effective low dose Abilify is.
Stay Up to Date with ME/CFS, Long COVID and Fibromyalgia News
Get Health Rising's free blogs featuring the latest findings and treatment options for the ME/CFS, long COVID, fibromyalgia and complex chronic disease communities.